[1]李梦依 罗强 张艺文 秦地茂 汪汉.代谢异常与原发性干燥综合征患者合并2型糖尿病风险的剂量-效应关系[J].心血管病学进展,2023,(5):476.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.021]
　LI MengyiLUO QiangZHANG Yiwen,QIN DimaoWANG Han.Dose-Response Relationship Between Metabolic Abnormalities and the Risk of Combined Type 2 Diabetes Mellitus in Patients with Primary Sjogren’s Syndrome[J].Advances in Cardiovascular Diseases,2023,(5):476.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.021]
点击复制

代谢异常与原发性干燥综合征患者合并2型糖尿病风险的剂量-效应关系()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年5期
页码:
476
栏目:
论著
出版日期:
2023-05-25

文章信息/Info

Title:
Dose-Response Relationship Between Metabolic Abnormalities and the Risk of Combined Type 2 Diabetes Mellitus in Patients with Primary Sjogren’s Syndrome
作者:
李梦依 罗强 张艺文 秦地茂 汪汉
(成都市第三人民医院心内科 西南交通大学附属医院 成都市心血管病研究所,成都 四川 610031)
Author(s):
LI MengyiLUO QiangZHANG Yiwen;  QIN DimaoWANG Han
(Department of Cardiology,The Third People’s Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Cardiovascular Disease Research Institute of Chengdu,Chengdu 610031,Sichuan,China)
关键词:
原发性干燥综合征; 糖尿病; 收缩压; 血糖
Keywords:
Primary Sj?gren syndrome; Diabetes mellitus; Systolic blood pressure; Blood glucose
DOI:
10.16806/j.cnki.issn.1004-3934.2023.05.021
摘要:
目的 探讨原发性干燥综合征(pSS)合并2型糖尿病(T2DM)患者的代谢异常情况(血压、血糖、血脂水平），并绘制代谢因素与pSS-T2DM风险之间的剂量-效应关系图。方法 本研究为病例对照研究，共纳入2009年1月1日 —2020年12月31日在成都市第三人民医院住院就诊的pSS患者，共737例，其中pSS-T2DM患者195例。经过年龄和性别匹配，最终纳入55例pSS-T2DM患者，110例pSS患者，110例健康对照组。结果 与不合并T2DM的pSS患者相比，合并T2DM的pSS患者收缩压(SBP)、肌酐、胆固醇、空腹血糖( P值均＜0.05)的水平较高。多因素logistic回归分析显示：SBP(OR＝1.03,95% Cl 1.00～1.06, P＝0.04）、胆固醇(OR＝1.82,95% Cl 1.05～3.16, P＝0.03）、空腹血糖（OR＝2.99,95% Cl 1.26～7.08， P＝0.01）与T2DM相关。剂量-效应曲线显示SBP与T2DM发病风险之间存在剂量-效应关系（总体关联检验：P＝0.01；非线性关联检验：P＝0.78；AIC＝196.85）。同样，观察到空腹血糖与T2DM发病风险之间存在剂量-效应关系（总体关联检验：P＜0.01；非线性关联检验：P＝0.10；AIC＝97.90）。结论 在pSS患者中，SBP、空腹血糖水平与T2DM发生风险呈线性剂量-效应关系，且pSS-T2DM患者比单纯pSS患者更易出现代谢异常。
Abstract:
Objective To investigate the differences in the levels of metabolic abnormalities (blood pressure,glucose,and lipids) in patients with primary Sjogren’s syndrome (pSS) combined with type 2 diabetes mellitus (T2DM) compared with patients with pSS alone and other populations,and to plot the dose-response relationship between metabolic factors and the risk of pSS-T2DM. Methods A total of 737 patients with pSS hospitalized in The Third People’s Hospital of Chengdu from January 1,2009 to December 31,2020 were enrolled in this case-control study ,including 195 patients with pSS-T2DM. After 1∶2∶2 matching for age and sex,55 patients with pSS-T2DM,110 patients with pSS,and 110 controls were finally included. Results Compared with pSS patients without combined T2DM,pSS patients with combined T2DM had higher values of systolic blood pressure ( SBP) (P＝0.01),creatinine (P＝0.02),cholesterol (P＝0.04),and fasting glucose (P＜0.01). Multifactorial logistic regression analysis showed that SBP (OR＝1.03,95% Cl 1.00～1.06, P＝0.04),cholesterol (OR＝1.82,95% Cl 1.05～3.16, P＝0.03),fasting glucose (OR＝2.99,95% Cl 1.26～7.08, P＝0.01) were correlated with T2DM. Dose-response curves showed a linear association between SBP and the risk of developing T2DM (overall association test:P＝0.01;non-linear association test:P＝0.78;AIC＝196.85). Similarly,a linear dose-response association was observed between fasting glucose and the risk of developing T2DM (overall association test:P＜0.01;non-linear association test:P＝0.10,AIC＝97.90). Conclusions There was a linear dose-response relationship between SBP,fasting glucose levels and the risk of developing T2DM in patients with pSS,and patients with pSS-T2DM were more likely to develop metabolic abnormalities than patients with pSS alone

参考文献/References:

[1] Qin L,Zhang Y,Yang X,et al. Cardiac involvement in primary Sj?gren’s syndrome[J]. Rheumatol Int,2022,42(2):179-189.

[2] Salman-Monte TC,Sanchez-Piedra C,Fernandez Castro M,et al. Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sj?gren syndrome[J]. Rheumatol Int,2020,40(8):1259-1265.

[3]Smolen JS,Aletaha D,McInnes IB. Rheumatoid arthritis[J].?Lancet,2016,388(10055):2023-2038.

[4] Brito-Zerón P,Kostov B,Solans R,et al. Systemic activity and mortality in primary Sj?gren syndrome:predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients[J]. Ann Rheum Dis,2016,75(2):348-355.

[5] Liu XZ,Gao Y,Fan J,et al. Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus[J]. Clin Rheumatol,2018,37(1):219-226.

[6] Puttevils D,de Vusser P,Geusens P,et al. Increased cardiovascular risk in patients with rheumatoid arthritis:an overview[J]. Acta Cardiol,2014,69(2):111-118.

[7] Yan L,Xu MT,Yuan L,et al. Prevalence of dyslipidemia and its control in type 2 diabetes:a multicenter study in endocrinology clinics of China[J]. J Clin Lipidol,2016,10(1):150-160.

[8] Ji L,Zhi X,Lu J,et al. Hyperglycemia and blood pressure treatment goal:a cross sectional survey of 18350 patients with type 2 diabetes in 77 tertiary hospitals in China[J]. PLoS One,2014,9(8):e103507.

[9] Baek S,Park SH,Won E,et al. Propensity score matching:a conceptual review for radiology researchers[J]. Korean J Radiol,2015,16(2):286-296.

[10]Jones NR,McCormack T,Constanti M,et al. Diagnosis and management of hypertension in adults:NICE guideline update 2019[J]. Br J Gen Pract,2020,70(691):90-91.

[11] Hoyo C,Cook MB,Kamangar F,et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas:a pooled analysis from the International BEACON Consortium[J]. Int J Epidemiol,2012,41(6):1706-1718.

[12] Xu S,Ilyas I,Little PJ,et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond:from mechanism to pharmacotherapies[J]. Pharmacol Rev,2021,73(3):924-967.

[13] Strehl C,Bijlsma JW,de Wit M,et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations:viewpoints from an EULAR task force[J]. Ann Rheum Dis,2016,75(6):952-957.

相似文献/References:

[1]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
　ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[2]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(5):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[3]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
　XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[4]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[5]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
　ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(5):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[6]麦尔耶姆·瓦热斯 罗心平 周鹏.糖尿病与心力衰竭：2型糖尿病是心力衰竭的独立危险因素？[J].心血管病学进展,2020,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
　Maieryemu·Waresi,LUO Xinping,ZHOU Peng.Diabetes and Heart Failure: Is Type 2 Diabetes an Independent Risk Factor for Heart Failure?[J].Advances in Cardiovascular Diseases,2020,(5):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
[7]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[8]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
　GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(5):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
[9]杨帆 吴建军.五味子乙素通过半胱天冬酶凋亡途径对抗高糖诱导的心肌细胞氧化应激损伤[J].心血管病学进展,2022,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.022]
　YANG Fan,WU Jianjun.Sch.B Protects High Glucose-Induced Cardiomyocytes from Oxidative Stress Injury via Caspase Pathway[J].Advances in Cardiovascular Diseases,2022,(5):188.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.022]
[10]杨晓晓 王峰 罗善顺 石立力.利拉鲁肽对糖尿病合并动脉粥样硬化模型中骨保护素的影响及机制研究[J].心血管病学进展,2022,(8):753.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.021]
　YANG Xiaoxiao,WANG Feng,LUO Shanshun,et al.The effect and Mechanism of Liraglutide on Osteoprotegerin?n Diabetic Atherosclerosis Rat[J].Advances in Cardiovascular Diseases,2022,(5):753.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.021]

更新日期/Last Update: 2023-06-29